Dina Schneider

In my current role with Cartesian Therapeutics I am responsible for execution of our company’s R&D Discovery strategy. Namely, I lead a division focused on the discovery and development of novel non-viral cell therapies for autoimmune disease, from inception to IND nomination. In my previous role as the Director of Immuno-Oncology and Cell Therapy at Lentigen Technology, Inc., a Miltenyi Biotec Company, I oversaw the discovery and pre-clinical development of chimeric antigen receptor (CAR) cell therapies for hematologic and solid tumors, and autoimmune disease. Among our successes were the development of Miltenyi’s lead investigational product Zamtocabtagene Autoleucel, and CAR19 employed in the first in the world efficacious and safe CAR T cell therapy for autoimmune disease. During my ten-year tenure with Miltenyi, I authored multiple patents for CAR T cell technology and helped initiate and manage several IIT clinical trials using the CliniMACS Prodigy platform for automated cell manufacturing. I am highly skilled in people and project management, team building, strategy development and problem solving. My leadership philosophy is to assemble highly efficient, motivated teams that allow for collaborative ownership of ideas and support professional growth of their members. My core technical competencies include immuno-oncology, immunology, cell and molecular biology, adoptive immunotherapy, tumor antigen escape, multi-targeting CARs, inducible switch-regulated CARs, xenograft models, viral and non-viral gene delivery methods. My mission is to leverage my expertise and passion for cell therapy to advance the science and practice of cancer and other diseases, and improve the lives of patients. I am always eager to collaborate with other experts and stakeholders in the field, and to share my knowledge and insights through publications and presentations.